Abstract
The rapid rise of chemical biology aimed at studying signaling networks for basic cellular activities using specific, active small molecules as probes has greatly accelerated research on pathological mechanisms and target therapy of diseases. This research is especially important for malignant tumors such as leukemia, a heterogeneous group of hematopoietic malignancies that occurs worldwide. With the use of a chemical approach combined with genetic manipulation, great progress has been achieved over the past few decades on the biological, molecular and cytogenetic aspects of leukemia, and in its diagnosis and therapy. In particular, discoveries of the clinical effectiveness of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia and the kinase inhibitors Imatinib and Dasatinib in the treatment of chronic myelogenous leukemia not only make target therapy of leukemia a reality, but also push mechanisms of leukemogenesis and leukemic cell activities forward. This review will outline advances in chemical biology that help our understanding of the molecular mechanisms of cell differentiation and apoptosis induction and target therapy of leukemia.
Similar content being viewed by others
Article PDF
References
Austin CP . The completed human genome: implications for chemical biology. Curr Opin Chem Biol 2003; 7: 511–5.
Friedman A, Perrimon N . Genome-wide high-throughput screens in functional genomics. Curr Opin Genet Dev 2004; 14: 470–6.
Doudna JA . Chemical biology at the crossroads of molecular structure and mechanism. Nat Chem Biol 2005; 1: 300–3.
Lipinski C, Hopkins A . Navigating chemical space for biology and medicine. Nature 2004; 432: 855–61.
Sawyer TK . Chemical biology and drug design: three-dimensional, dynamic, and mechanistic nature of two multidisciplinary fields. Chem Biol Drug Des 2006; 67: 196–200.
Lewis JD . The role of the chemical biology core facility at EMBL: a vision for a European roadmap. ACS Chem Biol 2007; 2: 21–3.
Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007; 109: 1810–6.
Tallman MS, Gilliland DG, Rowe JM . Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–63.
Scandura JM, Boccuni P, Cammenga J, Nimer SD . Transcription factor fusions in acute leukemia: variations on a theme. Oncogene 2002; 21: 3422–44.
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–72.
Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 1999; 96: 6318–23.
Kogan SC . Mouse models of acute promyelocytic leukemia. Curr Top Microbiol Immunol 2007; 313: 3–29.
Lutz PG, Moog-Lutz C, Cayre YE . Signaling revisited in acute promyelocytic leukemia. Leukemia 2002; 16: 1933–9.
Strudwick S, Borden KL . Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia 2002; 16: 1906–17.
Licht JD . Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate a cute promyelocytic leukemia?. Cancer Cell 2006; 9: 73–4.
Chen GQ, Shen ZX, Wu F, Han JY, Miao JM, Zhong HJ, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996; 10: 825–8.
Kambhampati S, Verma A, Li Y, Parmar S, Sassano A, Platanias LC . Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk Lymphoma 2004; 45: 2175–85.
Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li X, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia 2004; 18: 285–92.
Deubzer H, Busche B, Ronndahl G, Eikel D, Michaelis M, Cinatl J, et al. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells. Leuk Res 2006; 30: 1167–75.
Huang Y, Zhao Q, Chen GQ . Phospholipid scramblase 1. Sheng Li Xue Bao 2006; 58: 501–10.
Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 2004; 104: 3731–8.
Zhao KW, Li D, Zhao Q, Huang Y, Silverman RH, Sims PJ, et al. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem 2005; 280: 42707–14.
Huang Y, Zhao Q, Zhou CX, Gu ZM, Li D, Xu HZ, et al. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene 2006; 25: 6618–27.
Yokoyama A, Yamashita T, Shiozawa E, Nagasawa A, Okabe-Kado J, Nakamaki T, et al. MmTRA1b/phospholipid scramblase 1 gene expression is a new prognostic factor for acute myelogenous leukemia. Leuk Res 2004; 28: 149–57.
Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8–13.
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–60.
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–8.
Sanz MA, Fenaux P, Lo Coco F . Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231–5.
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326–34.
Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J . Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97: 2218–24.
Lu D P, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136–43.
Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O'Leary JJ, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001; 6: 4–11.
Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–32.
George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M . Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia 2004; 18: 1587–90.
Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A . Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 2002; 70: 292–9.
Rojewski MT, Korper S, Schrezenmeier H . Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004; 45: 2387–401.
Tallman MS . Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Blood Rev 2001; 15: 133–42.
Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z . Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20: 7146–53.
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052–61.
Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978–83.
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–53.
Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S . Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893–903.
Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772–8.
Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003; 63: 1853–9.
Berenson JR, Yeh HS . Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clin Lymphoma Myeloma 2006; 7: 192–8.
Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000; 14: 431–8.
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262–70.
Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia 2003; 17: 2065–73.
Jiang Y, Xue ZH, Shen WZ, Du KM, Yan H, Yu Y, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 2005; 19: 1239–47.
Liu W, Guo M, Xu YB, Li D, Zhou ZN, Wu YL, et al. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood 2006; 107: 698–707.
Yan H, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, et al. Hypoxia-simulating agents and selective stimulation of arsenic tri-oxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica 2005; 90: 1607–16.
Xue ZH, Jiang Y, Yu Y, Wang LS, Chen GQ, Zhao Q . Metavana-date suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. Biochem Biophys Res Commun 2005; 332: 1140–5.
Chen GQ, Peng ZG, Liu W, Song LP, Jiang Y, Huang Y, et al. Hypoxia inducible factor-1alpha and leukemic cell differentiation. Sheng Li Xue Bao 2006; 58: 5–13.
Song LP, Zhang J, Wu SF, Huang Y, Zhao Q, Cao JP, et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene 2007 Jul 16; [Epub ahead of print].
Peng ZG, Zhou MY, Huang Y, Qiu JH, Wang LS, Liao SH, et al. Acute myeloid leukemia-1 antagonizes transcriptional activity of hypoxia inducible factor-1alpha protein through direct protein-protein interaction. Oncogene 2007; in press.
Kim JS, Cho EW, Chung HW, Kim IG . Effects of Tiron, 4,5-dihydroxy-1,3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. Toxicology 2006; 223: 36–45.
Yuan W, Payton JE, Holt MS, Link DC, Watson MA, DiPersio JF, Ley TJ . Commonly dysregulated genes in murine APL cells. Blood 2007; 109: 961–70.
Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R, et al. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 2000; 97: 6757–62.
Nguyen-Khac F, Della Valle V, Lopez RG, Ravet E, Mauchauffe M, Friedman AD, et al. Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation. Oncogene 2006; 25: 4840–7.
Zhivotovsky B, Orrenius S . Carcinogenesis and apoptosis: paradigms and paradoxes. Carcinogenesis 2006; 27: 1939–45.
Huang Z . The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Chem Biol 2002; 9: 1059–72.
Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, Sacchi A . Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene 1995; 10: 731–7.
Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, et al. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms. Blood 2005; 105: 3714–21.
Liu W, Zhu YS, Guo M, Yu Y, Chen GQ . Therapeutic efficacy of NSC606985, a novel camptothecin analog, in acute myeloid leukemic mice. Leukemia Res 2007 Apr 9 [Epub ahead of print].
Lu Y, Xu YB, Yuan TT, Song MG, Lubbert M, Fliegauf M, et al. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 2006; 20: 987–93.
Yu Y, Wang LS, Shen SM, Xia L, Zhang L, Zhu YS, et al. Subcellular proteome analysis of camptothecin analog NSC606985-treated acute myeloid leukemic cells. J Proteome Res 2007 July 27. [Epub ahead of print].
Reed JC, Pellecchia M . Apoptosis-based therapies for hemato-logic malignancies. Blood 2005; 106: 408–18.
Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002; 100: 1828–34.
Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Dohner H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002; 100: 3749–56.
Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, Chang KS . Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J Biol Chem 2003; 278: 12294–304.
Zhou M, Gu L, Zhu N, Woods WG, Findley HW . Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003; 22: 8137–44.
Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005; 105: 804–11.
Takada Y, Andreeff M, Aggarwal BB . Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005; 106: 641–9.
Li X, Xu YB, Wang Q, Lu Y, Zheng Y, Wang YC, et al. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. J Cell Physiol 2006; 208: 594–601.
Zhang L, Wang LS, Xu Y, Xia L, Chen WL, Zheng Y, et al. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Chin J Physiol 2006; 49: 182–91.
Gao FH, Wang Q, Wu YL, Li X, Zhao KW, Chen GQ . c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. Biochem Biophys Res Commun 2007; 356: 505–11.
Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–53.
Kharas MG, Fruman DA . ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005; 65: 2047–53.
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–9.
Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109: 4143–50.
Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2006; 109: 3207–13.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported in part by the National Key Program (973) for Basic Research of China (No 2002CB512805), Key Project for International Collaboration of Ministry of Science and Technology of China (No 2003DF000038) and National Natural Science Foundation of China (No 90408009 and 30500257). Grants from the Science and Technology Committee of Shanghai (No 03XD14016, 05JC14032) should also be acknowledged.
Rights and permissions
About this article
Cite this article
Chen, Gq., Wang, Ls., Wu, Yl. et al. Leukemia, an effective model for chemical biology and target therapy. Acta Pharmacol Sin 28, 1316–1324 (2007). https://doi.org/10.1111/j.1745-7254.2007.00680.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00680.x
Keywords
This article is cited by
-
Current advances in the application of proteomics in apoptosis research
Science China Life Sciences (2011)
-
Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells
Chinese Science Bulletin (2009)